Editor-in-Chief
Assistant Professor
Department of Nutrition, Health and oncology
Moulay Ismail University
Morocco
View More
Editor-in-Chief
Associate Professor
Department of Genetics and Bioengineering
Yeditepe University
Turkey
View More
Editor-in-Chief
Director-cum-Principal
Pharmacy
Amity University Madhya Pradesh, Gwalior, India
India
View More
Editor-in-Chief
Professor
Hepatitis and AIDS
Pasteur Institute of Iran
Iran
View More
The Journal of Oncology Research and Therapy (JONT) is an open-access journal that focuses on disseminating research in oncology and targeted therapies The journal aims to facilitate the global exchange of knowledge and promote collaboration among researchers, clinicians, and healthcare professionals
developments in cancer biology, diagnosis, treatment, and precision medicine. The journal serves as a comprehensive platform for researchers, clinicians, and healthcare professionals who are committed to improving outcomes for cancer patients through innovation in targeted therapies and translational oncology
JORTT focuses on all aspects of oncological research, with particular emphasis on the development and application of targeted therapies, immunotherapies, molecular diagnostics, personalized treatment approaches, and biomarker-driven clinical trials. The journal welcomes original research articles, reviews, case studies, and short communications that contribute to a deeper understanding of tumour biology, resistance mechanisms, drug development, and therapeutic strategies
The scope of JORTT spans a wide range of cancer types, including but not limited to breast, lung, gastrointestinal, genitourinary, haematological, and paediatric cancers. It also covers emerging areas such as cancer genomics, epigenetics, systems biology, and artificial intelligence in oncology
By fostering interdisciplinary collaboration and providing a global forum for scientific exchange, JORTT aims to accelerate the translation of laboratory discoveries into effective clinical applications. The journal maintains a rigorous peer-review process to ensure the publication of high-quality, impactful research that drives progress in oncology and enhances patient care
With a mission to support evidence-based practice and promote innovation in cancer treatment, JORTT aspires to be a leading resource for oncologists, researchers, and industry professionals working toward a future where cancer is more effectively managed and ultimately cured.
Authors are requested to submit manuscripts online at Submit Manuscript or Send as an e-mail attachment to the Editorial Office at editorialoffice@confseries.net
Rapid Publication Service
Confseries Publishing is offering wide range of opportunities, options and services for the prospective authors to publish their scholarly contributions.
The journal caters to the demands of the fast publication without compromising on the editorial quality including manuscript peer-review. This flexibility is being provided to ensure earliest author credibility to their respective contributions and this will also ensure timely dissemination of research outcomes for efficient integration, effective translation and reduced redundancy.
Authors have the option to choose between the standard open access publication service which takes its own course of time for complete publication process or can opt for rapid publication service wherein the article is published at the earliest date (Includes multiple subject experts commissioning for securing earliest peer-review comments). The authors can avail this flexibility based on the personal preference, funding agency guidelines or Institutional or organizational requirements.
Regardless of the option, all manuscripts undergo thorough peer-review process, editorial assessment and production process.
Fast Editorial Execution and Review Process (FEE-Review Process)
Authors who are willing to publish their articles under this mode can make a pre-payment of $99 towards express peer-review and editorial decision. First editorial decision in 3 days and final decision with review comments in 5 days from the date of submission. Galley proof generation will be done in next 2 days from acceptance or maximum 5 days (For manuscripts notified for revision by external reviewer).
Manuscripts accepted for publication will be charged regular APC.
Authors retain the copyright of their publication and the final version of the article will be published in both HTML and PDF formats as well as XML formats for transmitting to indexing databases. The editorial team of the Journal will ensure adherence to scientific publication guidelines.
Confseries is an open-access platform that publishes thousands of manuscripts from internationally renowned researchers. Every submission is evaluated by our peer reviewers for suitability, and a full description of the peer review process appears below.
At Confseries, peer review is a vital part of our publishing process, ensuring that every manuscript undergoes a rigorous and unbiased evaluation.Each submission is carefully examined by subject experts who provide constructive feedback on improvements or confirm whether the work is ready for publication. To guarantee fairness and thoroughness, manuscripts are assigned to multiple reviewers, each offering their own independent assessment. The review is conducted under a double-blind system, maintaining confidentiality for both authors and reviewers.
Authors are expected to revise their manuscripts in line with reviewer suggestions and then resubmit them for further evaluation. On resubmission, the paper is reviewed again-sometimes by the original reviewers, and at other times by new ones. This review-and-revision cycle continues until the editorial board is fully satisfied that the manuscript meets the standards required for publication.
Confseries places the highest emphasis on research integrity and quality. Our peer review process is collaborative and iterative, reflecting a shared commitment between authors, reviewers, and editorial board members to uphold excellence in scholarly publishing.
